Two different regulatory questions

Health technology companies sometimes assume that falling outside HIPAA means they fall outside regulation. The Federal Trade Commission has repeatedly shown that this assumption is wrong. HIPAA status is one question. Another is whether a company makes claims to consumers, collects health information, or handles that information in a way that conflicts with what it told people.

The FTC’s authority over unfair and deceptive practices, reflected in the United States Code, applies to any company that makes claims to consumers, including companies that may not be covered by HIPAA. A business cannot avoid scrutiny by calling itself a technology company, a marketing platform, or a service that operates before a patient relationship begins.

This distinction matters because consumer-facing operations often start before clinical care. A person may see an advertisement, complete a health quiz, or submit information through an intake form without becoming a patient. The relevant policy questions include whether the eventual provider is covered by HIPAA, what the company promised, what information it collected, and how it used that information. For a related discussion, see when health apps asked whether HIPAA applied to them.

Claims create obligations

If an app says that it protects data in a particular way but does not follow that practice, the FTC can treat the statement as deceptive whether or not HIPAA applies. The same principle applies to health claims that a company cannot substantiate.

Privacy and health statements are therefore more than marketing language. A statement about data protection creates an expectation against which the company’s actual practices can be assessed. A statement about health outcomes or benefits raises a separate question about whether the company has support for the claim.

A disclaimer about HIPAA coverage does not resolve either issue. The HIPAA requirements collected in the Code of Federal Regulations do not make a company outside HIPAA free to describe its data practices inaccurately or make health claims it cannot support. The absence of HIPAA coverage does not allow a company to make wider promises or describe its data handling inaccurately.

The FTC also enforces its health breach notification rule for entities outside HIPAA. This extends the policy concern beyond the traditional clinical record. Health information can remain relevant to consumer protection even when the company handling it is not operating as a HIPAA-covered entity.

The marketing funnel is part of health privacy

The clinical side of a GLP-1 platform is generally under HIPAA. The marketing funnel, quiz, analytics, and advertising pixels fall within the FTC’s area of concern. This division matters because the first collection of sensitive information can take place well before a clinician reviews it.

The FTC has brought actions in related categories involving health information collected before a person became a patient and then passed to advertising networks. Information supplied during an apparently health-related interaction can enter an advertising system without the consumer understanding that this is happening or receiving enough information about the practice.

This can create a gap between the protections people assume apply and the point at which information is actually collected. A consumer may focus on a provider’s clinical handling of information while the data trail begins with a marketing page or quiz. Our GLP-1 clinic rankings examine data handling as part of that policy question, including the difference between clinical operations and the consumer-facing funnel.

The issue applies to many types of health technology companies. A business may create exposure when its advertising, analytics, or intake practices do not match what consumers are told. When a company uses health-related information to attract or sort prospective customers, the pre-intake stage requires close attention.

Why pre-intake data matters

The pre-intake stage deserves specific attention because it is the part least likely to receive the protections people assume apply. A person can provide information in response to a health-related prompt without understanding whether the information will go to a provider, a technology company, or an advertising network. The company’s disclosures determine whether the use is adequately explained, but a disclosure cannot correct an inaccurate description.

Evaluating a provider therefore requires review beyond the clinical encounter. What does the provider say about data collected before intake? Does its privacy description match the way the business operates? Are its health-related claims supported? These questions connect consumer protection with health data governance without treating HIPAA as the only relevant boundary.

The FTC’s role complements HIPAA but does not depend on it. HIPAA may govern the clinical side of an operation, while the FTC can address deceptive claims, unsupported health statements, and health information practices outside that framework. The result is a regulatory structure in which the marketing funnel remains part of the health privacy question rather than an area outside it.